Xometry price target raised to $42 from $34 at JMP Securities
JMP Securities raised the firm’s price target on Xometry (XMTR) to $42 from $34 and keeps an Outperform rating on the shares. The stock ...
Acrivon Therapeutics: Promising Clinical Data and Strategic Progress Justify Buy Rating
In a report released yesterday, Etzer Darout from BMO Capital reiterated a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research ...